Moderately to severely active Ulcerative Colitis (UC) research hub

A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects with Moderately to Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy

This study looks at a medicine called Entyvio for children and teenagers with moderate to severe ulcerative colitis. It aims to see if Entyvio helps them stay in remission (when symptoms improve or disappear) and if it's safe to use over time.